<DOC>
	<DOCNO>NCT02388724</DOCNO>
	<brief_summary>The purpose study demonstrate efficacy vonoprazan ( TAK-438 ) versus lansoprazole treatment erosive esophagitis classify Los Angeles ( LA ) classification grade A D Week 8 .</brief_summary>
	<brief_title>Efficacy Safety Oral Once-Daily Vonoprazan ( TAK-438 ) Participants With Erosive Esophagitis</brief_title>
	<detailed_description>The drug test study call vonoprazan . Vonoprazan test treat people erosive esophagitis . This study look mucosal heal people take vonoprazan versus lansoprazole . This study enroll approximately 480 patient . Participants randomly assign ( chance , like flip coin ) one two treatment groups—which remain undisclosed patient study doctor study ( unless urgent medical need ) : - Vonoprazan 20 mg - Lansoprazole 30 mg All participant ask take one tablet one capsule time day throughout study . All participant ask record daytime nighttime ( sleep ) subjective symptom diary daily basis . This multi-centre trial conduct worldwide . The overall time participate study 11 week . Participants make multiple visit clinic , contact telephone 7-14 day last dose study drug follow-up assessment .</detailed_description>
	<mesh_term>Esophagitis</mesh_term>
	<mesh_term>Lansoprazole</mesh_term>
	<mesh_term>Dexlansoprazole</mesh_term>
	<criteria>1 . In opinion investigator , participant capable understand comply protocol requirement . 2 . The participant , applicable , participant 's legally acceptable representative sign date write , informed consent form require privacy authorization prior initiation study procedure . 3 . Has confirm endoscopy erosive esophagitis , ie , Los Angeles ( LA ) classification grade A D within 7 day start Day 1 ( Visit 2 ) . Note : The recruitment goal ensure LA classification grade C/D account 30 % participant enrol ( 144/480 ) , recruitment grade A/B consider account 70 % ( 336/480 ) participant . 4 . Is age 18 year old old ( local age consent older ) , male female , time signing informed consent , treat outpatient basis erosive esophagitis , include admit temporarily examination . 5 . A female participant childbearing potential sexually active nonsterilized male partner agree use routinely adequate contraception signing inform consent throughout duration study . 1 . Has receive investigational compound within 84 day prior start Observation phase . 2 . Has receive TAK438 previous clinical study therapeutic agent . 3 . Is immediate family member , study site employee , dependant relationship study site employee involve conduct study ( eg , spouse , parent , child , sibling ) may consent duress . 4 . Has , judgment investigator , clinically significant abnormal hematological parameter hemoglobin , hematocrit , erythrocytes Screening . 5 . Has history clinical manifestation serious central nerve system ( CNS ) , cardiovascular , pulmonary , hepatic , renal , metabolic , gastrointestinal , urological , endocrine hematological disease . 6 . Has history hypersensitivity allergy TAK438 ( include excipients* ) proton pump inhibitor ( PPIs ) . *Dmannitol , crystalline cellulose , hydroxypropyl cellulose , fumaric acid , croscarmellose sodium , magnesium stearate , hypromellose , macrogol 6000 , titanium oxide , yellow iron sesquioxide iron sesquioxide . 7 . Has history drug abuse ( define illicit drug use ) history alcohol abuse within 1 year prior Observation Phase ( Visit 1 ) . 8 . Is required take exclude medication . 9 . If female , participant pregnant lactate intend become pregnant , , within 1 month participate study ; intend donate ova time period . 10 . Has participate another clinical study within past 30 day Visit 1 . 11 . Has comorbidities could affect esophagus ( eosinophilic esophagitis , esophageal varix , scleroderma , viral fungal infection , esophageal stricture ) , history radiotherapy cryotherapy esophagus ; corrosive physiochemical injury ( possible inclusion study Schatzki 's ring Barrett 's esophagus ) . 12 . Has history surgical procedure may affect esophagus ( eg , fundoplication mechanical dilatation esophageal strictures exclude Schatzki 's ring ) history gastric duodenal surgery exclude endoscopic removal benign polyp . 13 . Developed acute upper gastrointestinal bleeding , gastric ulcer ( mucosal defect white coating ) duodenal ulcer ( mucosal defect white coating ) , within 30 day start Observation Phase ( Visit 1 ) ( possible inclusion gastric duodenal erosion ) . 14 . Has ZollingerEllison syndrome gastric acid hypersecretion history gastric acid hypersecretion . 15 . Is schedule surgery require hospitalization require surgical treatment his/her participation study . 16 . Has history malignancy treat malignancy within 5 year start Observation Phase ( Visit 1 ) ( participant may include study he/she cure cutaneous basal cell carcinoma cervical carcinoma situ ) . 17 . Has acquire immunodeficiency syndrome ( AIDS ) hepatitis , include hepatitis virus carrier : hepatitis B surface antigen ( HBsAg ) positive , hepatitis C virus ( HCV ) antibodypositive ( participant may include study he/she HCVantigen HCVribonucleic acid [ RNA ] negative ) . 18 . Laboratory test perform start Early Observation Phase ( visit 1 ) reveal follow abnormality participant : 1 . Creatinine level : &gt; 2 mg/dL ( &gt; 177 μmol/L ) . 2 . Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) , total bilirubin level : &gt; upper limit normal ( ULN ) . 19 . Is active Screening Period closure enrollment identify Sponsor number participant randomize LA classification A/B C/D reach require sample size .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>